Management of advanced cutaneous T-cell lymphoma: role of the dermatologist in the multidisciplinary team.
作者信息
Poligone B, Querfeld C
机构信息
University of Rochester Medical Center, Rochester, NY, U.S.A.
City of Hope Comprehensive Cancer Center, Duarte, CA, U.S.A.
出版信息
Br J Dermatol. 2015 Oct;173(4):1081-3. doi: 10.1111/bjd.13849. Epub 2015 Aug 27.
Abstract
摘要
相似文献
1
Management of advanced cutaneous T-cell lymphoma: role of the dermatologist in the multidisciplinary team.晚期皮肤T细胞淋巴瘤的管理：皮肤科医生在多学科团队中的作用。
Br J Dermatol. 2015 Oct;173(4):1081-3. doi: 10.1111/bjd.13849. Epub 2015 Aug 27.
2
The academic health center in a disrupted world.动荡世界中的学术健康中心。
Pharos Alpha Omega Alpha Honor Med Soc. 2015 Spring;78(2):2-9.
3
Making decisions on resectability and injectability status of lesions in the management of advanced melanoma in Germany, France and the UK.在德国、法国和英国的晚期黑色素瘤治疗中，对病灶的可切除性和可注射性状态进行决策。
Eur J Dermatol. 2016 Oct 1;26(5):477-486. doi: 10.1684/ejd.2016.2821.
4
[Multidisciplinary approaches--the role of doctors].[多学科方法——医生的角色]
Nihon Rinsho. 2015 Feb;73 Suppl 2:667-70.
5
Director of Nursing Perceptions of Physicians' Roles in US Nursing Homes.美国养老院护理主任对医生角色的看法。
J Am Med Dir Assoc. 2019 Nov;20(11):1471-1473. doi: 10.1016/j.jamda.2019.05.006. Epub 2019 Jul 1.
6
It's hard to be a real doctor now.现在很难成为一名真正的医生。
Pharos Alpha Omega Alpha Honor Med Soc. 2015 Autumn;78(4):66-7.
7
Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.伏立诺他（Zolinza）用于皮肤T细胞淋巴瘤。
Med Lett Drugs Ther. 2007 Mar 12;49(1256):23-4.
8
Caring for patients with cancer. Family physicians' role.关爱癌症患者。家庭医生的角色。
Can Fam Physician. 1994 Jan;40:16-9.
9
A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.米替福新治疗皮肤T细胞淋巴瘤患者的II期试验。
Bull Cancer. 2006 Nov;93(11):E115-8.
10
[Interferon alpha in the treatment of cutaneous T-cell lymphoma].[干扰素α治疗皮肤T细胞淋巴瘤]
Ann Dermatol Venereol. 2005 Sep;132 Spec No 2:5S27-30.
引用本文的文献
1
The Landscape of Cutaneous T-Cell Lymphoma (CTCL) in the Middle East and North Africa (MENA) and the Establishment of the MENA CTCL Working Group.中东和北非地区皮肤T细胞淋巴瘤（CTCL）的概况以及中东和北非皮肤T细胞淋巴瘤工作组的成立
Cancers (Basel). 2024 Oct 2;16(19):3380. doi: 10.3390/cancers16193380.
2
The impact of a multidisciplinary clinic on diagnosis and management of patients with cutaneous T-cell lymphoma.多学科诊所对皮肤T细胞淋巴瘤患者诊断和管理的影响。
Arch Dermatol Res. 2024 Sep 28;316(9):651. doi: 10.1007/s00403-024-03399-x.
3
Role of Antigenic Stimulation in Cutaneous T-Cell Lymphomas.抗原刺激在皮肤 T 细胞淋巴瘤中的作用。
J Invest Dermatol. 2024 Apr;144(4):755-763. doi: 10.1016/j.jid.2023.10.023. Epub 2023 Dec 26.
4
Overcoming Chemotherapy Resistance in Cutaneous T-Cell Lymphoma: A Successful Case of High-Dose Radiotherapy Management.克服皮肤T细胞淋巴瘤的化疗耐药性：高剂量放射治疗管理的成功案例
Cureus. 2023 Aug 23;15(8):e43959. doi: 10.7759/cureus.43959. eCollection 2023 Aug.
5
Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.加拿大博纳吐珠单抗治疗皮肤 T 细胞淋巴瘤的成本效益：与甲氨蝶呤或贝沙罗汀相比，医生的选择。
Adv Ther. 2023 May;40(5):2326-2338. doi: 10.1007/s12325-023-02470-9. Epub 2023 Mar 15.
6
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.随机 3 期 ALCANZA 研究比较 brentuximab vedotin 与皮肤科医生选择治疗皮肤 T 细胞淋巴瘤：最终数据。
Blood Adv. 2021 Dec 14;5(23):5098-5106. doi: 10.1182/bloodadvances.2021004710.
7
Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases.皮肤 T 细胞淋巴瘤患者用罗米地辛治疗难治性瘙痒：一系列 4 例报告。
Dermatol Ther. 2019 Mar;32(2):e12804. doi: 10.1111/dth.12804. Epub 2019 Jan 4.
本文引用的文献
1
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.原发性皮肤 T 细胞淋巴瘤（蕈样肉芽肿和赛泽里综合征）：第一部分。诊断：临床和组织病理学特征以及新的分子和生物学标志物。
J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049.
2
Changing incidence trends of cutaneous T-cell lymphoma.皮肤 T 细胞淋巴瘤发病率变化趋势。
JAMA Dermatol. 2013 Nov;149(11):1295-9. doi: 10.1001/jamadermatol.2013.5526.
3
Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma.细菌毒素促进皮肤 T 细胞淋巴瘤的疾病进展。
Toxins (Basel). 2013 Aug 14;5(8):1402-21. doi: 10.3390/toxins5081402.
4
Incidence and survival patterns of cutaneous T-cell lymphomas in the United States.美国皮肤 T 细胞淋巴瘤的发病和生存模式。
Leuk Lymphoma. 2013 Apr;54(4):752-9. doi: 10.3109/10428194.2012.729831. Epub 2013 Jan 7.
5
Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin.接受罗米地辛治疗的皮肤 T 细胞淋巴瘤患者瘙痒有临床意义的减轻。
Leuk Lymphoma. 2013 Feb;54(2):284-9. doi: 10.3109/10428194.2012.711829. Epub 2012 Aug 17.
6
Pruritus in cutaneous T-cell lymphoma: a review.皮肤 T 细胞淋巴瘤的瘙痒：综述。
J Am Acad Dermatol. 2012 Oct;67(4):760-8. doi: 10.1016/j.jaad.2011.12.021. Epub 2012 Jan 30.
7
Early CTCL diagnosis, a (miR)age no more?
Blood. 2011 Nov 24;118(22):5717-8. doi: 10.1182/blood-2011-09-379107.
8
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.蕈样肉芽肿和塞扎里综合征的临床终点和反应标准：国际皮肤淋巴瘤学会、美国皮肤淋巴瘤联盟以及欧洲癌症研究与治疗组织皮肤淋巴瘤工作组的共识声明。
J Clin Oncol. 2011 Jun 20;29(18):2598-607. doi: 10.1200/JCO.2010.32.0630. Epub 2011 May 16.
9
Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.蕈样肉芽肿/赛泽里综合征的生存结局和预后因素：修订的国际皮肤淋巴瘤学会/欧洲癌症研究与治疗组织分期建议的验证。
J Clin Oncol. 2010 Nov 1;28(31):4730-9. doi: 10.1200/JCO.2009.27.7665. Epub 2010 Sep 20.
10
Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat.皮肤 T 细胞淋巴瘤中的瘙痒：常见、常严重且难以治疗。
Acta Derm Venereol. 2010;90(1):12-7. doi: 10.2340/00015555-0789.
Zotero 插件